Navigation Links
Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share
Date:5/23/2013

s been to ensure that such information has been correctly and fairly reproduced or presented (and no steps have been taken by the directors of Royalty Pharma to verify this information).  To the best of the knowledge and belief of the directors of Royalty Pharma (having taken all reasonable care to ensure that such is the case), the information contained in this announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

The managing member of RP Management accepts responsibility for the information contained in this announcement, save that the only responsibility accepted by the managing member of RP Management in respect of the information in this announcement relating to Elan, the Elan Group, the Board of Elan and the persons connected with them, which has been compiled from published sources, has been to ensure that such information has been correctly and fairly reproduced or presented (and no steps have been taken by the managing member of RP Management to verify this information).  To the best of the knowledge and belief of the managing member of RP Management (having taken all reasonable care to ensure that such is the case), the information contained in this announcement for which he accepts responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

J.P. Morgan, together with its affiliate J.P. Morgan Cazenove (which is authorised and regulated by the Financial Conduct Authority in the United Kingdom), is acting exclusively for Royalty Pharma and RP Management in connection with the matters described in this announcement and for no one else, and is not, and will not be, responsible to anyone other than Royalty Pharma and RP Management for providing the protections afforded to clients of J.P. Morgan or its affiliates, or for providing advice in relati
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Royalty Rates Take Center Stage in Biopharma Dealmaking
2. Royalty Pharma Announces Proposal To Acquire Elan
3. PDL BioPharma Provides First Quarter 2013 Royalty Revenue Guidance of $92 Million
4. Royalty Rates for Pharmaceuticals & Biotechnology: Real-Deal Information for Hundreds of Transactions
5. PDL BioPharma Completes Structured Financing and Royalty Transaction with Avinger
6. Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
7. Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash
8. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
9. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
10. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
11. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015 Amgen (NASDAQ: ... two pivotal Phase 3, global, randomized, placebo-controlled trials ... treatment of secondary hyperparathyroidism (SHPT) in patients with ... met the primary endpoint, demonstrating that a greater ... achieved a greater than 30 percent reduction in ...
(Date:5/29/2015)... Pa. , May 29, 2015 ... focus of the Association for the Advancement of ... With support from AAWC,s corporate partners, ... Educational Portal on the AAWC website at ... a wound care pathway with links to various ...
(Date:5/28/2015)... 2015 Zimmer Holdings, Inc. (NYSE and SIX: ... with buyers to divest in the United ... assets, Biomet Discovery® Elbow System assets and Cobalt™ bone ... Zimmer,s pending acquisition of Biomet, Inc. ("Biomet").  ... constructively with the Bureau of Competition Staff of the ...
Breaking Medicine Technology:Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7The Association for the Advancement of Wound Care Educates the Public 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6
... Reportlinker.com announces that a new market research ... Triple Analysis: Lung Cancer, Lymphoma ... This triple analysis ... both Lung Cancer and Lymphoma and by ...
... 23, 2011 Applied Medical today announced that it ... Covidien) on May 17, 2011 in the U.S. District ... a recently issued Applied Medical trocar seal patent by ... Action No. CV 11-4203 VBF (AJWx). The patent is ...
Cached Medicine Technology:Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 2Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 3Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 4Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 5Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent 2
(Date:5/30/2015)... May 30, 2015 You've probably heard that ... and hearing loss. However, have you found a better way ... Olathe, Kan., have exactly what you need. , They developed ... build-up; dirt and dead, dry skin from the ears. What's ... swabs or anything on the market today for children and ...
(Date:5/30/2015)... The results of a 40+ year study in ... to cause mesothelioma, regardless of the volume of exposure. ... Surviving Mesothelioma website. , The study conducted by ... found that, among the 138 cases of mesothelioma that ... of them happened at plants that had, at some ...
(Date:5/30/2015)... 30, 2015 ProIntro Magnify contains 30 self-animating ... animations. Instantly add an elegant opening title to any ... range of clean design layouts. ProIntro Magnify is created exclusively ... extremely easy to use. Simply drag a preset into the ... and parameters in the Inspector window then watch as ProIntro ...
(Date:5/30/2015)... At 73 years old, Lynn Kendall ... which she attributes to a lifetime of being health-conscious. She ... the release of her new book titled “ Cook for ... for Health and Longevity” features a collection of recipes and ... food . It is designed to encourage a lifestyle of ...
(Date:5/30/2015)... CA (PRWEB) May 30, 2015 ... today that she is offering a free analysis and ... The offer coincides with Disability Awareness Month, which was ... Industry members across the United States such as Polk ... to raise awareness about the possibility of disability, as ...
Breaking Medicine News(10 mins):Health News:Improved Ear Hygiene Tool Invented by InventHelp Clients (KSC-952) 2Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Announcing the release of ProIntro Magnify from Pixel Film Studios. 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 3Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2
... MAKO Surgical Corp., a,developer of minimally invasive, ... that Frederic H. Moll, M.D.,has been named to ... Dr. Moll has over 20 years experience ... Hansen Medical Inc. in September 2002 and,currently serves ...
... Sept. 14 NNN Healthcare/Office REIT,Inc. has acquired ... closed on September 10, 2007. 2750 Monroe ... 106,000 square feet, as well as an accessory ... square feet, on a 10.5-acre parcel,in the Valley ...
... is a,Statement by Oscar S. Wyatt, Jr.: "I,ve seen some press reports about candidates for ... funds received from me, please return them in the form of a,donation to the DeBakey Medical ... ... ...
... AMERIGROUP,Corporation (NYSE: AGP ) will host an Investor ... held at the Grand Hyatt Hotel in New York ... management team,beginning at 8:30 a.m. Eastern Time. The ... of,AMERIGROUP,s National Advisory Board on Improving Healthcare Services for,Seniors ...
... following is a,statement by Mike Leavitt, Secretary of Health ... Rich McKeown, returns to Beijing as the,head of a ... my,Department, to begin formal negotiations on two binding Agreements ... of food and feed, and one on,the safety of ...
... PRGO ; TASE) today announced that President and CEO, ... a review of the Company,business for the financial community ... in New York. The meeting will be made ... or by phone at 866-383-5538, participant,code 10972. Presentations ...
Cached Medicine News:Health News:MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors 2Health News:NNN Healthcare/Office REIT Acquires 2750 Monroe Boulevard in Valley Forge, Pennsylvania 2Health News:NNN Healthcare/Office REIT Acquires 2750 Monroe Boulevard in Valley Forge, Pennsylvania 3Health News:AMERIGROUP Corporation to Host Investor Day 2Health News:Perrigo Company to Host Analyst Meeting on September 18, 2007 2
... of America is the largest, ... lab network in the United ... Crizal coating centers, Essilor offers ... premium quality on the best-selling ...
Bambi database allows images, analytical results, and eyebank or clinical information to be stored in an easy-to-access database. In most cases, the analytical results from any of our analysis progra...
This computerized retail software is aimed for opticians/optometrists, optical chains/1 hr superstores, optical HMOs, and ophthalmology groups....
... SDS Recall marketing software enables the efficient ... The module also has many built-in time ... auto capitalization of name fields and numerous ... and accurate data input. The pre-defined options ...
Medicine Products: